A study published on CD44+ monocytes identifies a mechanistic driver of inflammation in bronchopulmonary dysplasia (BPD) among very premature infants. By focusing on monocyte subsets bearing CD44, researchers mapped how these cells contribute to hyperinflammatory signaling that sustains lung injury in early life. The findings sharpen the biological target set for BPD, a chronic neonatal lung disease linked to long-term morbidity. Instead of treating the syndrome broadly, the work emphasizes a defined immune-cell state—CD44+ monocytes—as a lever in disease progression. For translational teams, the study increases the odds of immune-modulating interventions landing with more specificity, provided follow-on work validates whether blocking CD44-dependent pathways improves clinical outcomes.